How TB500 works
TB500 is the active fragment of Thymosin beta-4 and binds actin, the cytoskeletal protein cells use to move. Upregulating actin turnover lets endothelial cells and fibroblasts migrate into injury sites, so it works on the mobility side of repair where BPC 157 works on the supply side.
Reported benefits
- Improved joint mobility and flexibility
- Systemic rather than purely local repair action
- Reduced scar-tissue formation
- Supports endothelial and muscle cell migration
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Injection-site reactions
- Fatigue or flu-like feeling after early doses
- Head-rush, headache
- No completed human safety trials
Serious or rare signals
- WADA-prohibited; proliferative activity is a theoretical cancer concern
Regulatory status & sources
Not FDA approved. Thymosin beta-4 has been studied in early trials for corneal and cardiac repair only.
Safety note
TB500 is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.